Judah Schorr
IDTAbout Judah Schorr
Judah Schorr (age 73) is an independent director of IDT Corporation, serving on the Board since December 2006. He is a physician-entrepreneur: founder and President of Judah Schorr MD PC (anesthesia services), President of Tutto Anesthesia, attending physician at Bergen Regional Medical Center (NJ), and Managing Partner of Chavrusa Realty Corp. He holds a B.S. in Psychology from Brooklyn College and an M.D. from the University of Trieste Faculty of Medicine and Surgery .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Judah Schorr MD PC | Founder & President | Since 1994 | Built and led anesthesia provider operations |
| Tutto Anesthesia (subsidiary) | President | Not disclosed | Managed anesthesia services expansion |
| Bergen Regional Medical Center | Attending Physician | Not disclosed | Clinical practice; no IDT interlock |
| Chavrusa Realty Corp. | Managing Partner | Not disclosed | Commercial real estate management |
External Roles
| Organization | Role | Public/Private | Notes |
|---|---|---|---|
| Judah Schorr MD PC | President/Owner | Private | Healthcare services |
| Tutto Anesthesia | President | Private | Healthcare services |
| Bergen Regional Medical Center | Attending Physician | Public hospital (not a public company board) | No disclosed interlock with IDT |
| Chavrusa Realty Corp. | Managing Partner | Private | Real estate |
No other public company directorships disclosed .
Board Governance
- Independence: Board determined Dr. Schorr is independent; no relationships required consideration for independence review .
- Tenure: Director since December 2006; Board nominee in 2024 and 2025 .
- Attendance: In FY2024 and FY2025, each director attended or participated in ≥75% of scheduled Board and committee meetings; Board met 9 times in FY2024 and 8 times in FY2025 (four regularly scheduled each year) .
- Executive sessions: Held at every regularly scheduled Board meeting; presided by Lead Independent Director Eric F. Cosentino .
- Committee assignments (current and prior year):
- Audit Committee: Member; FY2025 composition Katsof (Chair), Cosentino, Schorr; FY2024 composition Chenkin (Chair), Cosentino, Schorr .
- Compensation Committee: Member; FY2025 composition Cosentino (Chair), Katsof, Schorr; FY2024 composition Cosentino (Chair), Chenkin, Schorr .
- Corporate Governance Committee: Member; FY2025 composition Cosentino (Chair), Katsof, Schorr; FY2024 composition Cosentino (Chair), Chenkin, Schorr .
- Nominating Committee: Member; FY2025 and FY2024 composition Cosentino (Chair), Schorr .
Fixed Compensation
| Component | FY2024 | FY2025 |
|---|---|---|
| Annual Board cash retainer ($) | $50,000 | $50,000 |
| Committee fees ($) | None | None |
| Meeting fees ($) | None disclosed | None disclosed |
| Lead Independent Director stipend ($) | N/A for Schorr; role held by Cosentino ($50,000) | N/A for Schorr; role held by Cosentino ($50,000) |
| Total cash ($) | $50,000 | $50,000 |
Performance Compensation
| Equity Award Type | Grant Date | Shares | Vesting | Grant-Date Fair Value ($) |
|---|---|---|---|---|
| Restricted Class B shares | Jan 5, 2024 | 1,476 | Vested in full on grant | $50,000 (valued by avg high/low prior day; reported $50,169 in comp table) |
| Restricted Class B shares | Jan 6, 2025 | 1,053 | Vested in full on grant | $49,991 (valuation basis avg high/low prior day; reported $50,291 in comp table) |
Performance metrics tied to director compensation: None disclosed; director equity awards vest immediately and are not performance-conditioned .
Other Directorships & Interlocks
| Entity | Relationship | Notes |
|---|---|---|
| None | Public company boards | No other public company directorships disclosed |
| Related party transactions | None attributed to Schorr | Corporate Governance Committee oversees related person transactions; 2024–2025 related-party disclosures primarily involve Howard S. Jonas and family-controlled entities, not Schorr . |
Expertise & Qualifications
- Physician and healthcare operations entrepreneur; leadership and compliance insight from long tenure on Audit, Compensation, Corporate Governance, and Nominating Committees .
- Academic credentials: B.S. Psychology (Brooklyn College), M.D. (University of Trieste) .
- The Nominating Committee and Board cite his entrepreneurial management experience as valuable to IDT oversight .
Equity Ownership
| Metric | As of Oct 18, 2024 | As of Oct 17, 2025 |
|---|---|---|
| Beneficial ownership (Class B shares) | 127,518 (<1%) | 128,571 (<1%) |
| Direct holdings | 120,386 | 121,439 |
| Trust holdings | 7,000 (Schorr Family Trust) | 7,000 (Schorr Family Trust) |
| IRA holdings | 132 | 132 |
| Director shares held for service (Class B) | 70,386 | 71,439 |
| Options outstanding | None (non-employee directors) | None (non-employee directors) |
Note: Percent ownership is reported as less than 1% per IDT’s beneficial ownership table (assumes conversion of Class A to Class B) .
Governance Assessment
-
Strengths:
- Independence and engagement: Schorr meets NYSE and company independence standards; participates across all core committees and attended ≥75% of meetings; executive sessions held every regular meeting under a Lead Independent Director .
- Alignment: Above-average director ownership versus peers (e.g., ~128k Class B shares vs. low holdings by other non-employee directors), plus annual equity grants, supports skin-in-the-game and incentive alignment .
- Committee coverage: Schorr’s presence across Audit, Compensation, Governance, and Nominating provides comprehensive oversight breadth .
-
Risks and potential red flags:
- Controlled company structure: IDT qualifies as a “controlled company” under NYSE rules with majority voting power held by Howard S. Jonas; while IDT voluntarily maintains independent majorities and fully independent Compensation and Governance Committees, the controlled status and extensive related-party transactions with Jonas-affiliated entities remain governance risk factors for minority holders .
- Nominating/Corporate Governance exception: IDT utilizes separate Corporate Governance and Nominating committees and avails itself of the NYSE controlled-company exception to not have a single combined Nominating/Governance Committee; mitigated by both committees being fully independent .
- No performance-conditioned director pay: Director equity awards vest immediately and are not tied to performance metrics, which can reduce pay-for-performance linkage for directors .
Overall, Schorr’s long tenure, committee breadth, and notable personal share ownership are positives for board effectiveness and investor alignment; governance risks primarily stem from the controlled-company environment and related-party transactions overseen by the Corporate Governance Committee .